Abstract
OBJECTIVE: This study evaluates the efficacy of VELVERT, a novel antimicrobial dressing, compared to the standard Silver Sulfadiazine dressing in treating second-degree burns. METHOD: Conducted at a tertiary burn care center, 63 patients were enrolled and randomized into two groups: VELVERT (n = 31) and Silver Sulfadiazine (n = 30). The primary outcomes measured were wound closure percentage and time to complete healing within 24 days, while secondary outcomes included infection control, pain relief, and adverse events. The study was registered with CTRI with the registration number CTRI/2020/12/029698 (https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NDY5MDc=&Enc=&userName=). RESULT: Among 61 patients who completed the study, 87% (27/31) in the VELVERT group achieved complete wound healing compared to 63% (19/30) in the Silver Sulfadiazine group. The BWAT score, assessing wound healing, showed a decline from 31.66 ± 3.15 to 15.55 ± 4.42 in the VELVERT group and from 31.55 ± 3.35 to 16.18 ± 5.37 in the Silver Sulfadiazine group (P = 0.176). Both treatments were well tolerated, but VELVERT exhibited superior wound healing outcomes. CONCLUSION: These findings suggest that VELVERT may serve as a more effective alternative for second-degree burn treatment, offering improved healing rates. Further research with larger sample sizes is recommended to validate its clinical benefits over standard treatments.